Cohort characteristics | no. | % |
---|---|---|
Male | 25 | 69 |
Age, years, median (range) | 60.5 (25–77) | |
Symptom onset to sampling, days, median (range) | 18 (9–53) | |
Days since diagnosis (positive SARS-CoV-2 PCR), median (range) | 8 (1–44) | |
Comorbidities | ||
Diabetes mellitus type II | 13 | 36 |
Hypertension | 11 | 31 |
Lung disease | 8 | 22 |
Cardiovascular disease | 7 | 19 |
BMI > 25 | 6 | 17 |
Malignancy | 3 | 8 |
Treatment | ||
Supplemental oxygen | 33 | 92 |
Mechanical ventilation | 9 | 25 |
ICU addmissiona | 14 | 39 |
Immunomodulatory drugsb | 14 | 39 |
Antiviral treatment (remdesivir) | 2 | 6 |